Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Immunogenicity of V114 in Healthy Infants in South Korea
NCT04633226Phase 3Completed
- Sponsor
- Merck & Co.
- Start
- Feb 2021
- Primary completion
- Nov 2022
- Modality
- Split/Subunit Vaccines
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of pneumococcal 15-valent conjugate vaccine in pneumococcal disease, sponsored by Merck & Co. Primary endpoints: Percentage of Participants With ≥1 Solicited Injection-site Adverse Events, Percentage of Participants With ≥1 Solicited Systemic Adverse Events and 4 more. Started Feb 2021; status: completed.
02
Drugs
pneumococcal 15-valent conjugate vaccine
03
Conditions
pneumococcal disease
Beyond the preview
Go deeper on NCT04633226.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04633226.